ARK THERAPEUTICS

Dead / Cancelled — Cancelled — Section 8 (as of 08 Mar 2019)

What this means for you

This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
77937687
Registration number
4184675
Mark type
Stylized text
Filed
17 Feb 2010
Published for opposition
03 Apr 2012
Registered
07 Aug 2012
Attorney of record
Leigh Ann Lindquist

Goods and services

  • Class 001 — Chemicals: Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research
  • Class 005 — Pharmaceuticals: Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements
  • Class 010 — Medical apparatus: Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites
  • Class 042 — Scientific and technological services: Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field

Owner

Prior registrations

Prosecution history

  • 08 Mar 2019 — CANCELLED SEC. 8 (6-YR)
  • 07 Aug 2017 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
  • 07 Aug 2012 — REGISTERED-PRINCIPAL REGISTER
  • 28 Jun 2012 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
  • 28 Jun 2012 — NOTICE OF ALLOWANCE CANCELLED
  • 28 Jun 2012 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 22 Jun 2012 — TEAS DELETE 1(B) BASIS RECEIVED
  • 29 May 2012 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 03 Apr 2012 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 03 Apr 2012 — PUBLISHED FOR OPPOSITION
  • 14 Mar 2012 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 27 Feb 2012 — LAW OFFICE PUBLICATION REVIEW COMPLETED
  • 21 Feb 2012 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 10 Feb 2012 — EXAMINER'S AMENDMENT ENTERED
  • 10 Feb 2012 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

View this trademark record on Marksy